-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Vaxart, Inc. (NASDAQ:VXRT) Stake Increased by Tower Research Capital LLC TRC
Vaxart, Inc. (NASDAQ:VXRT) Stake Increased by Tower Research Capital LLC TRC
Tower Research Capital LLC TRC lifted its stake in Vaxart, Inc. (NASDAQ:VXRT – Get Rating) by 147.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,073 shares of the biotechnology company's stock after acquiring an additional 51,953 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Vaxart worth $190,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of VXRT. State Street Corp increased its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company's stock worth $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. Barclays PLC increased its position in Vaxart by 6,969.5% during the third quarter. Barclays PLC now owns 656,117 shares of the biotechnology company's stock worth $1,430,000 after buying an additional 646,836 shares during the last quarter. UBS Group AG increased its position in Vaxart by 34.6% during the first quarter. UBS Group AG now owns 836,815 shares of the biotechnology company's stock worth $4,217,000 after buying an additional 214,901 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Vaxart by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 434,678 shares of the biotechnology company's stock worth $2,191,000 after buying an additional 214,197 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Vaxart by 28.7% during the first quarter. Bank of America Corp DE now owns 631,861 shares of the biotechnology company's stock worth $3,185,000 after buying an additional 140,833 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.
Get Vaxart alerts:Analysts Set New Price Targets
Separately, B. Riley lowered their target price on shares of Vaxart from $6.00 to $1.50 and set a "neutral" rating on the stock in a research report on Monday, December 19th.
Vaxart Price Performance
Vaxart stock opened at $0.81 on Tuesday. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.82. The company's fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.57. Vaxart, Inc. has a one year low of $0.73 and a one year high of $5.43.
Vaxart Profile
(Get Rating)
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.
Featured Articles
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT – Get Rating).
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
Tower Research Capital LLC TRC lifted its stake in Vaxart, Inc. (NASDAQ:VXRT – Get Rating) by 147.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,073 shares of the biotechnology company's stock after acquiring an additional 51,953 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Vaxart worth $190,000 as of its most recent filing with the Securities and Exchange Commission.
根据Tower Research Capital LLC向美国证券交易委员会披露的最新信息,Tower Research Capital LLC TRC在第三季度将其在Vaxart, Inc.(纳斯达克股票代码:VXRT — Get Rating)的股份提高了147.9%。该基金在本季度又收购了51,953股股票后,拥有这家生物技术公司的87,073股股票。截至最近向美国证券交易委员会提交的文件,Tower Research Capital LLC TRC拥有Vaxart约0.07%的股份,价值19万美元。
A number of other hedge funds have also modified their holdings of VXRT. State Street Corp increased its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company's stock worth $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. Barclays PLC increased its position in Vaxart by 6,969.5% during the third quarter. Barclays PLC now owns 656,117 shares of the biotechnology company's stock worth $1,430,000 after buying an additional 646,836 shares during the last quarter. UBS Group AG increased its position in Vaxart by 34.6% during the first quarter. UBS Group AG now owns 836,815 shares of the biotechnology company's stock worth $4,217,000 after buying an additional 214,901 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Vaxart by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 434,678 shares of the biotechnology company's stock worth $2,191,000 after buying an additional 214,197 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Vaxart by 28.7% during the first quarter. Bank of America Corp DE now owns 631,861 shares of the biotechnology company's stock worth $3,185,000 after buying an additional 140,833 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.
其他一些对冲基金也修改了持有的VXRT。State Street Corp在第一季度将其在Vaxart的股份增加了23.9%。State Street Corp在上个季度又收购了2673,332股股票后,现在拥有这家生物技术公司13,860,974股股票,价值69,859,000美元。巴克莱集团在第三季度将其在Vaxart的头寸增加了6,969.5%。巴克莱集团在上个季度又购买了646,836股股票后,现在拥有这家生物技术公司的656,117股股票,价值143万美元。瑞银集团股份公司在第一季度将其在Vaxart的头寸增加了34.6%。瑞银集团股份公司在上个季度又购买了214,901股股票后,现在拥有这家生物技术公司的836,815股股票,价值421.7万美元。高盛集团公司在第一季度将其在Vaxart的头寸增加了97.1%。高盛集团公司在上个季度又购买了214,197股股票后,现在拥有这家生物技术公司的434,678股股票,价值219.1万美元。最后,美国银行DE在第一季度将其在Vaxart的头寸增加了28.7%。美国银行股份公司在上个季度又购买了140,833股股票后,现在拥有这家生物技术公司的631,861股股票,价值318.5万美元。该股票的38.66%由机构投资者和对冲基金持有。
Analysts Set New Price Targets
分析师设定了新的价格目标
Separately, B. Riley lowered their target price on shares of Vaxart from $6.00 to $1.50 and set a "neutral" rating on the stock in a research report on Monday, December 19th.
另外,B. Riley在12月19日星期一的一份研究报告中将Vaxart股票的目标价格从6.00美元下调至1.50美元,并对该股设定了 “中性” 评级。
Vaxart Price Performance
Vaxart 价格表现
Vaxart stock opened at $0.81 on Tuesday. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.82. The company's fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.57. Vaxart, Inc. has a one year low of $0.73 and a one year high of $5.43.
Vaxart股票周二开盘价为0.81美元。该公司的市值为1.0579亿美元,市盈率为-0.97,beta值为0.82。该公司的五十天移动平均线价格为0.99美元,其两百天移动平均线价格为1.57美元。Vaxart, Inc. 创下一年低点0.73美元,一年高点为5.43美元。
Vaxart Profile
Vaxart 简介
(Get Rating)
(获取评分)
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.
Vaxart, Inc是一家临床阶段的生物技术公司,从事基于其Vector-Aduvant-Antigen标准化技术(VAAST)口服疫苗平台的口服重组疫苗的开发。其在研疫苗使用室温稳定的片剂而不是通过注射方式给药。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
- 免费获取 StockNews.com 关于 Vaxart 的研究报告 (VXRT)
- 去钱在哪里。这是最值得购买的三只银行股息股票
- 马伦汽车股票的另一种催化剂
- 太阳能科技服务;Nextracker 应该在你的关注范围内
- 随着锂需求的飙升,美国锂是安全的选择吗
- Highwoods Properties,折扣价高品质房地产
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT – Get Rating).
想看看还有哪些对冲基金持有 VXRT 吗? 访问Holdingschannel.com,获取Vaxart, Inc.(纳斯达克股票代码:VXRT — 获取评级)的最新13F文件和内幕交易。
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Vaxart Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Vaxart及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧